reports
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BEND...
Eagle Pharmaceuticals Announces $69 Million Agreement to Monetize BENDEKA® Royalties WOODCLIFF LAKE, N.J., March 31, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that it has entered into a royalty purchase agreement with an entity that was provided capital by funds managed by Blue Owl Capital Inc. (“Blue Owl”) (the “Agreement”), dated March 31, 2025, to sell the royalty interest in annual net sales of BENDEKA® (bendamustine hydrochloride injection) in the United States for an aggregate purchase price of $69 million before ...
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockhol...
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration stockholder rights plan (the “Rights Plan”) to increase the initial purchase price of each preferred share purchase right issued under the Rights Plan from $10.00 to $20.00, effective immediately. The Rights Plan otherwise remains unmodified and in ful...
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financi...
Eagle Pharmaceuticals Appoints Christopher Krawtschuk as Chief Financial Officer WOODCLIFF LAKE, N.J., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced the appointment of Christopher Krawtschuk as Chief Financial Officer (“CFO”) of the Company, effective November 11, 2024. In connection with Mr. Krawtschuk’s appointment, Mr. Steven Ratoff stepped down from his role as interim Chief Financial Officer and will remain as a director on the Company’s board of directors. “Chris is a talented finance executive with deep exp...
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan
Eagle Pharmaceuticals Adopts Limited Duration Stockholder Rights Plan WOODCLIFF LAKE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (the “Company” or “Eagle”) (OTCMKTS: EGRX) today announced that its Board of Directors (the “Board”) has adopted a limited duration stockholder rights agreement (the “Rights Plan”), effective immediately. The Company continues to experience a significant dislocation in the trading price of its common stock. The Rights Plan is intended to enable each of the Company’s stockholders to have the opportunity to realize the long-term value of ...
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from...
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on August 21, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that pursuant to Nasdaq Listing Rule 5810(d)(2), the Company’s failure to timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Q2 2024 Form 10-Q”) serves as an...
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from...
Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq WOODCLIFF LAKE, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company” or “Eagle”) today announced that it received a notice (the “Notice”) on May 20, 2024, from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it has initiated a process to delist the Company’s securities from Nasdaq because the Company had not filed its Form 10-Q for the quarter ended September 30, 2023 (the “Q3 2023 Form 10-Q”) and ...
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Ph...
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting Preliminary results from the Company’s ongoing Phase 2/3 study expected in the first half of 2025 WOODCLIFF LAKE, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will deliver a Trial in Progress presentation discussing the ongoing Phase 2/3 stu...
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial ...
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida -- Single dose, IV amisulpride (10 mg) results in sustained antiemetic effect with supratherapeutic plasma levels of drug being maintained for at least 24 hours in patients requiring PONV rescue versus placebo -- WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”)...
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency ...
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Annual Report on Form 10-K WOODCLIFF LAKE, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on April 8, 2024 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that due to the Company’s failure to timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “Form 10-K”), with the S...
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Pro...
Eagle Pharmaceuticals Provides Update on Bendamustine Intellectual Property Portfolio WOODCLIFF LAKE, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today provided an update on its bendamustine intellectual property portfolio. On January 16, 2024, the United States Court of Appeals for the Federal Circuit affirmed the previously announced decision by the United States District Court for the District of Delaware finding that the 505(b)(2) drug applications referencing BELRAPZO® filed by Slayback Pharma Limited Liability C...
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amis...
Eagle Pharmaceuticals to Present Abstract on Post-hoc Analysis of Amisulpride at the 77th PGA (PostGraduate Assembly in Anesthesiology) in New York City -- BARHEMSYS® (amisulpride) Injection is the first and only antiemetic approved by the U.S. Food and Drug Administration (“FDA”) for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV -- -- In patients who experience PONV, the incidence of nausea is substantially greater than the inc...
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency ...
Eagle Pharmaceuticals Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (the “Company”) today announced that it received a notice (the “Notice”) on November 27, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not currently in compliance with Nasdaq’s continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) (the “Rule”), which re...
Eagle Pharmaceuticals Announces Management Change
Eagle Pharmaceuticals Announces Management Change – CEO and Founder Scott Tarriff Retires – – Chairman Michael Graves to Serve as Interim Executive Chairman – WOODCLIFF LAKE, N.J., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced a change in management. Effective immediately Scott Tarriff, Founder, President and Chief Executive Officer of the Company, has announced his resignation and retirement from his positions with the Company as President, Chief Executive Officer and Director on the Company’s Board of Di...
Eagle Delays Third Quarter 2023 Results and Conference Call
Eagle Delays Third Quarter 2023 Results and Conference Call WOODCLIFF LAKE, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that it will be delaying the release of its third quarter 2023 results and investor conference call, previously scheduled for today, Thursday, November 9, 2023. The Company currently anticipates filing a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission no later than one business day after the due date of its Quarterly Report on Form 10-Q for the third qu...
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on ...
Eagle Pharmaceuticals to Host Third Quarter 2023 Financial Results on November 9, 2023 WOODCLIFF LAKE, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its third quarter 2023 financial results on Thursday, November 9, 2023, before the market opens. Scott Tarriff, President and Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will host a conference call to discuss the results as follows: DateTimeToll free (U.S.)InternationalThursday, November 9, 2023 8:30 a.m...
Eagle Pharmaceuticals Granted Patent for PEMFEXY®
Eagle Pharmaceuticals Granted Patent for PEMFEXY® WOODCLIFF LAKE, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Patent and Trademark Office has granted the Company U.S. Patent No. 11,793,813 (“the ‘813 patent”) entitled “Pemetrexed Formulations.” Eagle has submitted the patent for listing in the U.S. Food and Drug Administration’s Orange Book.1 The ‘813 patent is directed to pemetrexed formulations, including the FDA-approved commercial formulation of PEMFEXY®. The ‘813 patent will expire in 203...
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status fo...
Eagle Pharmaceuticals Granted Unique J-Code and Pass-Through Status for BARHEMSYS® from CMS -- J-code is effective January 1, 2024, and transitional pass-through status became effective October 1, 2023, facilitating patient access -- -- BARHEMSYS is the first and only antiemetic approved by the FDA for rescue treatment of postoperative nausea and vomiting (“PONV”) despite prophylaxis1 and is also approved for the treatment of PONV in patients who have not received prophylaxis and for the prevention of PONV -- WOODCLIFF LAKE, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE)...
Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented a...
Eagle Pharmaceuticals Awarded First Prize for Poster to Be Presented at the International Society for Anaesthetic Pharmacology 32nd Annual Meeting -- Study reports on an interim analysis of the pharmacokinetics and pharmacodynamics of remimazolam and a subsequent model-based optimization of the dosing regimen that is being studied in the trial -- -- Prize money to be donated to the University of Groningen Medical Center (“UMCG”) research fund, which supports the work of PhD students -- -- Eagle’s BYFAVO® (remimazolam) for injection is approved for sedation in adults undergoing...
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Confe...
Eagle Pharmaceuticals to Present at the Cantor Global Healthcare Conference 2023 WOODCLIFF LAKE, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference 2023 as follows: Date:Wednesday, September 27, 2023Time:2.25PM ETWebcast: To schedule a 1x1 meeting with management, please contact The webcast of the presentation will be accessible for 90 day...
Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 A...
Eagle Pharmaceuticals to Present CAL02 Trial in Progress at the 2023 ASM/ESCMID Joint Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance -- CAL02 is a unique therapeutic agent that is designed to work differently from antibiotics, aiming to disarm an infectious pathogen’s virulence factors to reduce damage and mitigate disease ---- The first-in-human study showed positive safety and efficacy when added to standard of care in patients with severe community-acquired bacterial pneumonia -- WOODCLIFF LAKE, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Eagle Pharmac...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.